141 related articles for article (PubMed ID: 29951752)
1. Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples.
Oono Y; Kuwata T; Takashima K; Shinmura K; Hori K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
Gastric Cancer; 2019 Mar; 22(2):335-343. PubMed ID: 29951752
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
[TBL] [Abstract][Full Text] [Related]
4. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer.
García I; Vizoso F; Martín A; Sanz L; Abdel-Lah O; Raigoso P; García-Muñiz JL
Ann Surg Oncol; 2003 Apr; 10(3):234-41. PubMed ID: 12679307
[TBL] [Abstract][Full Text] [Related]
6. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
[TBL] [Abstract][Full Text] [Related]
7. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Gumusay O; Benekli M; Ekinci O; Baykara M; Ozet A; Coskun U; Demirci U; Uner A; Dursun A; Atak EY; Buyukberber S
Jpn J Clin Oncol; 2015 May; 45(5):416-21. PubMed ID: 25732909
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
9. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
10. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
[TBL] [Abstract][Full Text] [Related]
12. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
13. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
Zhang J; Guo L; Liu X; Li W; Ying J
Oncotarget; 2017 Feb; 8(6):10264-10273. PubMed ID: 28052014
[TBL] [Abstract][Full Text] [Related]
14. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer.
Oono Y; Kuwata T; Takashima K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
Surg Endosc; 2018 Sep; 32(9):3964-3971. PubMed ID: 29500656
[TBL] [Abstract][Full Text] [Related]
16. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
17. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
18. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
[TBL] [Abstract][Full Text] [Related]
19. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
Kimura M; Tsuda H; Morita D; Shinto E; Tanimoto T; Ichikura T; Mochizuki H; Matsubara O
Jpn J Clin Oncol; 2005 Jun; 35(6):324-31. PubMed ID: 15928192
[TBL] [Abstract][Full Text] [Related]
20. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
